Abstract
Mycoplasma genitalium antimicrobial resistance is common in US sexual health clinics. Population-level prevalence is unknown. We tested National Health and Nutrition Examination Survey (2017–2018) specimens for M genitalium resistance mutations (n = 58). Macrolide resistance prevalence was 42.7% (95% CI, 24.4%–62.7%). Quinolone resistance was not detected. Macrolide resistance testing should guide azithromycin treatment.
Funding Information
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health (R01AI161019)

This publication has 12 references indexed in Scilit: